Clinical trial
Insulin Glargine "All to Target" Trial
NCT00384085 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00384085 |
|---|---|
| Title | Insulin Glargine "All to Target" Trial |
| Official title | All to Target Trial Lantus® (Insulin Glargine) With Stepwise Addition of APIDRA® (Insulin Glulisine) or Lantus With One Injection of Apidra vs a Twice-Daily Premixed Insulin Regimen (Novolog® Mix 70/30) in Adult Subjects With Type 2 Diabetes Failing Dual or Triple Therapy With Oral Agents: a… |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Insulin Glulisine, Insulin Glargine, Premixed Insulin |
| Enrollment | 588 |
| Start date | May 1, 2006 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Oct 4, 2006 |
| Last update posted | May 6, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: